JP2021531015A - アデノシンレベルを増加させることができる細菌株を使用する治療法 - Google Patents
アデノシンレベルを増加させることができる細菌株を使用する治療法 Download PDFInfo
- Publication number
- JP2021531015A JP2021531015A JP2021503787A JP2021503787A JP2021531015A JP 2021531015 A JP2021531015 A JP 2021531015A JP 2021503787 A JP2021503787 A JP 2021503787A JP 2021503787 A JP2021503787 A JP 2021503787A JP 2021531015 A JP2021531015 A JP 2021531015A
- Authority
- JP
- Japan
- Prior art keywords
- adenosine
- strain
- nucleotidase
- production
- strains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title claims abstract description 496
- 239000002126 C01EB10 - Adenosine Substances 0.000 title claims abstract description 248
- 229960005305 adenosine Drugs 0.000 title claims abstract description 248
- 238000011282 treatment Methods 0.000 title claims abstract description 53
- 230000001580 bacterial effect Effects 0.000 title description 93
- 238000004519 manufacturing process Methods 0.000 claims abstract description 111
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 102
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 51
- 239000004310 lactic acid Substances 0.000 claims abstract description 51
- 241000894006 Bacteria Species 0.000 claims abstract description 43
- 230000029663 wound healing Effects 0.000 claims abstract description 17
- 230000001939 inductive effect Effects 0.000 claims abstract description 15
- 230000007812 deficiency Effects 0.000 claims abstract description 13
- 108010043671 prostatic acid phosphatase Proteins 0.000 claims description 119
- 102000004008 5'-Nucleotidase Human genes 0.000 claims description 109
- 238000000034 method Methods 0.000 claims description 82
- 230000000694 effects Effects 0.000 claims description 69
- 208000027418 Wounds and injury Diseases 0.000 claims description 68
- 206010052428 Wound Diseases 0.000 claims description 67
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 66
- 201000010099 disease Diseases 0.000 claims description 64
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 42
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 34
- 230000001965 increasing effect Effects 0.000 claims description 32
- 239000006228 supernatant Substances 0.000 claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 14
- 230000004054 inflammatory process Effects 0.000 claims description 13
- 230000003779 hair growth Effects 0.000 claims description 11
- 210000000214 mouth Anatomy 0.000 claims description 11
- 230000009467 reduction Effects 0.000 claims description 11
- 238000012216 screening Methods 0.000 claims description 10
- 230000000699 topical effect Effects 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 9
- 210000004209 hair Anatomy 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 201000004384 Alopecia Diseases 0.000 claims description 6
- 230000000968 intestinal effect Effects 0.000 claims description 6
- 230000003712 anti-aging effect Effects 0.000 claims description 5
- 230000004968 inflammatory condition Effects 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 230000003676 hair loss Effects 0.000 claims description 3
- 208000024963 hair loss Diseases 0.000 claims description 3
- 230000005784 autoimmunity Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 23
- 230000006806 disease prevention Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 48
- 230000009885 systemic effect Effects 0.000 description 25
- 239000000047 product Substances 0.000 description 20
- 230000001684 chronic effect Effects 0.000 description 19
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 17
- 239000006041 probiotic Substances 0.000 description 17
- 235000018291 probiotics Nutrition 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 17
- 239000000758 substrate Substances 0.000 description 17
- 210000002421 cell wall Anatomy 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 210000002540 macrophage Anatomy 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000008901 benefit Effects 0.000 description 10
- 230000000770 proinflammatory effect Effects 0.000 description 10
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 231100000397 ulcer Toxicity 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000010187 selection method Methods 0.000 description 7
- 101150051188 Adora2a gene Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 238000002705 metabolomic analysis Methods 0.000 description 6
- 230000001431 metabolomic effect Effects 0.000 description 6
- 108010028584 nucleotidase Proteins 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 102100022464 5'-nucleotidase Human genes 0.000 description 5
- 206010009900 Colitis ulcerative Diseases 0.000 description 5
- 208000011231 Crohn disease Diseases 0.000 description 5
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 5
- 241000186660 Lactobacillus Species 0.000 description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 230000000529 probiotic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000011321 prophylaxis Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
- 108050000203 Adenosine receptors Proteins 0.000 description 4
- 102000009346 Adenosine receptors Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 3
- 241000553356 Lactobacillus reuteri SD2112 Species 0.000 description 3
- 210000004322 M2 macrophage Anatomy 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000003690 classically activated macrophage Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000001723 extracellular space Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000007407 health benefit Effects 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 101150078577 Adora2b gene Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010056340 Diabetic ulcer Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 201000004029 Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome Diseases 0.000 description 2
- 208000007027 Oral Candidiasis Diseases 0.000 description 2
- 208000007117 Oral Ulcer Diseases 0.000 description 2
- 208000006311 Pyoderma Diseases 0.000 description 2
- 241000287411 Turdidae Species 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 201000002996 androgenic alopecia Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000007784 diverticulitis Diseases 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- -1 lactic acid bacteria Chemical compound 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000004144 purine metabolism Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000007838 tissue remodeling Effects 0.000 description 2
- 239000003970 toll like receptor agonist Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000034619 Gingival inflammation Diseases 0.000 description 1
- 108010014095 Histidine decarboxylase Proteins 0.000 description 1
- 102100037095 Histidine decarboxylase Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000004551 Interleukin-10 Receptors Human genes 0.000 description 1
- 108010017550 Interleukin-10 Receptors Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 101100442557 Lactobacillus sp. (strain 30a) hdcA gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 208000032159 Vaginal inflammation Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 108700029631 X-Linked Genes Proteins 0.000 description 1
- 208000028247 X-linked inheritance Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229940071604 biogaia Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008975 immunomodulatory function Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 210000005026 intestinal epithelial barrier Anatomy 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000029774 keratinocyte migration Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000025687 phenotypic switching Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003658 preventing hair loss Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001696 purinergic effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 235000014107 unsaturated dietary fats Nutrition 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
a)5’−ヌクレオチダーゼ、例えば細胞壁に固定された5’−ヌクレオチダーゼをコードする遺伝子の存在について、細菌株、例えば乳酸菌株をスクリーニングすること、及び/又は
b)活性5’−ヌクレオチダーゼ酵素、例えば細胞壁に固定された5’−ヌクレオチダーゼ酵素の存在について、例えば乳酸菌株などの細菌株、又はその上清をスクリーニングすること
を含む。
を触媒し、この反応を測定するアッセイは、活性5’−ヌクレオチダーゼ酵素の存在(又は5’−ヌクレオチダーゼ活性)を決定するために容易に使用できる。言い換えれば、本明細書における活性又は機能的5’−ヌクレオチダーゼ酵素への言及は、適切な条件下で、例えばAMPなどの適切な基質が供給される場合に、この反応を触媒することができるものである。5’−ヌクレオチダーゼ酵素の活性は、例えばそのような酵素アッセイで、例えば、反応で産生され、測定又は定量化することができるリン酸、アデノシン、又はアデノシンの他の適切な下流産生物の量又は濃度を測定することによって、必要に応じて定量化することができる。活性は、細菌細胞のサンプル、又は細菌細胞からの上清で便利に測定することができる。
a)5’−ヌクレオチダーゼ、例えば細胞表面に固定された5’ヌクレオチダーゼをコードする遺伝子の存在について、乳酸菌株をスクリーニングすること、及び
b)5’−ヌクレオチダーゼ酵素の活性を定量化すること、及び任意選択で、
c)5’−ヌクレオチダーゼ酵素の活性が最も高い又は十分に高い乳酸菌株を選択すること
を含む、アデノシンの産生に有効な細菌株、好ましくは乳酸菌株を選択するための方法を提供することは、本発明のなおさらなる態様である。
(i)細菌株、例えば本発明の選択方法によって選択される、産生される、得られる、又は得ることができる乳酸菌株(又は本明細書で別途定義されるようにアデノシンを産生することができるかアデノシンの産生を誘導することができる細菌株)であって、細菌株が、細胞表面に固定された5’−ヌクレオチダーゼをコードする遺伝子又は活性5’ヌクレオチダーゼ酵素を有し、アデノシンを産生することができる、細菌株と、
(ii)アデノシンの産生を増加又は増強させる1又は複数の基質成分又は薬剤、あるいはそのような成分又は薬剤の供給源と
を含む組成物(又は組み合わせ製品又はキット)を提供する。
例1
5’−ヌクレオチダーゼに位置する細胞表面をコードする遺伝子を有する菌株を同定する方法
細菌をMRSプレート上で嫌気性雰囲気中37℃で16時間培養する。滅菌プラスチックループで10個の細菌コロニーを収集し、100マイクロリットルの滅菌水(PCR品質)に懸濁する。(代替法では、適切な方法を使用して細菌培養物からDNAを調製する。)
プライマーペア1(産物のサイズ233bp)
(配列番号2)
(配列番号3)
プライマーペア2(産物のサイズ212bp)
(配列番号4)
(配列番号5)
プライマーペア3(産物のサイズ232bp)
(配列番号6)
(配列番号7)
細胞表面に固定された5’−ヌクレオチダーゼをコードする遺伝子、GenBankアクセッション番号:AEI56270.1、LPXTG−モチーフ細胞壁アンカードメインタンパク質[ラクトバチルス・ロイテリ(Lactobacillus reuteri)SD2112](配列番号8)
細胞表面に固定された5’−ヌクレオチダーゼタンパク質、GenBankアクセッション番号:AEI56270.1、LPXTG−モチーフ細胞壁アンカードメインタンパク質[ラクトバチルス・ロイテリ(Lactobacillus reuteri)SD2112](配列番号9)
5’−ヌクレオチダーゼ活性を分析するための手順
Crystal Chem 5’−ヌクレオチダーゼアッセイキット(Crystal Chem、エルクグローブヴィレッジ、イリノイ州、米国)を使用して、細菌細胞及び発酵上清の5’−ヌクレオチダーゼ活性を測定した。要するに、手順は次の通りであった。
ラクトバチルス・ロイテリ(Lactobacillus reuteri)菌株の5’−ヌクレオチダーゼ活性
ラクトバチルス・ロイテリ(Lactobacillus reuteri)DSM32846、DSM32847、DSM32848、DSM32849、及びラクトバチルス・ロイテリ(Lactobacillus reuteri)DSM17938(2006年1月30日のDSMZ−Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH(Mascheroder Weg 1b,D−38124 Braunschweig)でブダペスト条約に基づいて寄託)における5’−ヌクレオチダーゼ活性を示す実験データは、上記の例2で説明した方法を使用して生成した。結果を図1に示す。
菌株の選択
上記の例3のすべての新しい菌株、すなわち、ラクトバチルス・ロイテリ(Lactobacillus reuteri)DSM32846、DSM32847、DSM32848、及びDSM32849は、細菌上清において5’−ヌクレオチダーゼ活性を示す。分析は、1mlあたり109個の細菌の濃度を有する細菌培養物の上清で実施した。
血漿中のアデノシンレベルに対する菌株の影響
材料及び方法
マウス.野生型(WT)C57BL/6Jマウス(6〜8週齢)をJackson Laboratoriesから購入し、実験前に2週間馴化させた。すべてのマウスは、ヒューストンにあるテキサス大学健康科学センターの特定病原体除去動物施設に収容された。この研究は、実験動物の管理と使用に関する指針(NIH)、施設内動物管理と使用委員会(IACUC)の推奨に従って実施された。プロトコルはIACUCによって承認された(プロトコル番号:AWC−14−056及び17−0045)。
メタボロミクス解析により、血漿アデノシンが検出された。ラクトバチルス・ロイテリ(Lactobacillus reuteri)DSM17938を健康な母乳飼養のマウスに毎日経口給餌すると、MRS給餌対照群(p<0.05)又は無処置群(p<0.01)のマウスと比較して、血漿アデノシンの強度スケールが有意に増加した(図2)。WT+LR/WT無処置の倍率変更は5.95であり、WT+LR/WT+MRSの倍率変更は4.4であった。WT+MRS群とWT無処置群との間に有意差はなかった。
ラクトバチルス・ロイテリ(Lactobacillus reuteri)菌株の5’−ヌクレオチダーゼ活性
ラクトバチルス・ロイテリ(Lactobacillus reuteri)DSM33198の5’−ヌクレオチダーゼ活性を示す実験データは、上記の例2で説明した方法を使用して生成された。結果は図3Aに示されており、図3Aでは、同じ実験のDSM17938の5’−ヌクレオチダーゼ活性(DSM17938活性=1)に関連して正規化されている。DSM17938の5’−ヌクレオチダーゼ活性(DSM17938活性=1)に関連する同じタイプの正規化を図1の結果にも行い、これは図3Bに示されており、異なる細菌株についてDSM17938に関連する5’−ヌクレオチダーゼ活性の倍率変更の比較を容易にしている。
菌株の選択
上記の例6の新しい菌株、すなわちラクトバチルス・ロイテリ(Lactobacillus reuteri)DSM33198は、細菌の上清で高い5’−ヌクレオチダーゼ活性を示す。分析は、1mlあたり109個の細菌の濃度を有する細菌培養物の上清で実施した。
<223>任意のアミノ酸
配列表2 <223>プライマーLrNuc1f
配列表3 <223>プライマーLrNuc1r
配列表4 <223>プライマーLrNuc2f
配列表5 <223>プライマーLrNuc2r
配列表6 <223>プライマーLrNuc3f
配列表7 <223>プライマーLrNuc3r
Claims (20)
- 対象におけるアデノシンの産生に使用するための、アデノシンを産生することができるかアデノシンの産生を誘導することができる乳酸菌株。
- 乳酸菌株が5’−ヌクレオチダーゼをコードする遺伝子を有するか、又は活性5’−ヌクレオチダーゼ酵素を有する、請求項1に記載の使用のための菌株。
- 使用が、アデノシンの欠損又は減少に関連する疾患又は状態の治療又は予防にある、請求項1又は請求項2に記載の使用のための菌株。
- 使用が創傷治癒のためである、請求項1から3のいずれか一項に記載の使用のための菌株。
- 使用が、皮膚治療、毛髪治療、炎症状態、Treg欠損症又はTreg機能不全に関連する疾患、又は自己免疫疾患のためである、請求項1から3のいずれか一項に記載の使用のための菌株。
- 使用が、局所、口腔及び/又は腸の傷、皮膚回復治療、老化防止治療、増毛又は発毛を促進又は増加させるため、脱毛を治療又は予防するため、胃腸管、泌尿生殖路、口腔、肺及び/又は気道、又は皮膚の炎症過程を治療又は予防するため、又はIPEX症候群を治療又は予防するためのものである、請求項4又は請求項5に記載の使用のための菌株。
- 菌株が2ユニット/L又は8ユニット/Lを超える5’−ヌクレオチダーゼ活性を有する、及び/又は2μmol・L−1分−1又は8μmol・L−1分−1を超えるレベルでアデノシンを産生することができるかアデノシンの産生を誘導することができる、請求項1から6のいずれか一項に記載の使用のための菌株。
- 菌株がラクトバチルス・ロイテリ(Lactobacillus reuteri)であり、好ましくは菌株がラクトバチルス・ロイテリ(Lactobacillus reuteri)DSM17938ではない、請求項1から7のいずれか一項に記載の使用のための菌株。
- 菌株がラクトバチルス・ロイテリ(Lactobacillus reuteri)DSM32846、DSM32847、DSM32848、DSM32849及び/又はDSM33198である、請求項1から8のいずれか一項に記載の使用のための菌株。
- 菌株が、ラクトバチルス・ロイテリ(Lactobacillus reuteri)DSM17938と比較して増加したレベルで、5’−ヌクレオチダーゼ活性を有する、及び/又はアデノシンを産生することができるかアデノシンの産生を誘導することができる、請求項1から9のいずれか一項に記載の使用のための菌株。
- 使用が、少なくとも1つのさらなる薬剤の投与をさらに含み、好ましくは、さらなる薬剤がAMP又はAMPの供給源である、請求項1から10のいずれか一項に記載の使用のための菌株。
- 請求項4から6のいずれか1項に定義された疾患又は状態の治療又は予防に使用するためのラクトバチルス・ロイテリ(Lactobacillus reuteri)菌株DSM32846、DSM32847、DSM32848、DSM32849、又はDSM33198。
- アデノシンを産生することができる乳酸菌株を選択する方法であって、方法が、
a)5’−ヌクレオチダーゼをコードする遺伝子の存在について乳酸菌株をスクリーニングすること、及び/又は
b)活性5’−ヌクレオチダーゼ酵素の存在について、乳酸菌株又はその上清をスクリーニングすること、及び
c)アデノシンを産生することができる菌株を選択すること
を含み、
さらに、方法によって選択される菌株は、対象におけるアデノシンの産生に使用するためのものであり、好ましくは、使用は、請求項4から6のいずれか一項に定義される通りである、方法。 - 菌株が、2ユニット/Lを超える5’−ヌクレオチダーゼ活性を有する、及び/又は2μmol・L−1分−1を超えるレベルでアデノシンを産生することができ、好ましくは8ユニット/Lを超える活性を有する、及び/又は8μmol・L−1分−1を超えるレベルでアデノシンを産生することができるように選択される、請求項13に記載の方法。
- 菌株がラクトバチルス・ロイテリ(Lactobacillus reuteri)である、請求項13から14のいずれか一項に記載の方法。
- アデノシンを産生することができるかアデノシンの産生を誘導することができる有効量の乳酸菌株を対象に投与するステップを含む、対象においてアデノシンを産生する方法。
- 対象におけるアデノシンの産生に使用するための薬剤又は組成物の製造における、アデノシンを産生することができるかアデノシンの産生を誘導することができる乳酸菌株の使用。
- 創傷治癒、皮膚治療、毛髪治療、炎症状態、Treg欠損症又はTreg機能不全に関連する疾患、又は自己免疫疾患から選択される疾患又は状態の治療のための請求項16又は請求項17に記載の方法又は使用。
- 局所、口腔及び/又は腸の傷、皮膚回復治療、老化防止治療、増毛又は発毛を促進又は増加させるため、脱毛を治療又は予防するため、胃腸管、泌尿生殖路、口腔、肺及び/又は気道、又は皮膚の炎症過程を治療又は予防するため、もしくはIPEX症候群を治療又は予防するための、請求項18に記載の方法又は使用。
- 菌株又は疾患又は対象又は投与が、請求項2から11のいずれか一項に定義されている、請求項16から19のいずれか一項に記載の方法又は使用。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1812079.0A GB201812079D0 (en) | 2018-07-24 | 2018-07-24 | Selection method |
GB1812079.0 | 2018-07-24 | ||
GB1905470.9 | 2019-04-17 | ||
GBGB1905470.9A GB201905470D0 (en) | 2019-04-17 | 2019-04-17 | Selection method |
GBGB1905591.2A GB201905591D0 (en) | 2019-04-18 | 2019-04-18 | Therapeutic method |
GB1905591.2 | 2019-04-18 | ||
PCT/EP2019/069987 WO2020020984A1 (en) | 2018-07-24 | 2019-07-24 | Therapeutic methods using bacterial strains which are capable of increasing adenosine levels |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021531015A true JP2021531015A (ja) | 2021-11-18 |
JPWO2020020984A5 JPWO2020020984A5 (ja) | 2022-07-05 |
Family
ID=67383783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021503787A Pending JP2021531015A (ja) | 2018-07-24 | 2019-07-24 | アデノシンレベルを増加させることができる細菌株を使用する治療法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230057324A1 (ja) |
EP (1) | EP3827102A1 (ja) |
JP (1) | JP2021531015A (ja) |
CN (1) | CN112739814B (ja) |
CA (1) | CA3103356A1 (ja) |
MX (1) | MX2020014222A (ja) |
WO (1) | WO2020020984A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021531739A (ja) * | 2018-07-24 | 2021-11-25 | バイオガイア・エイビーBiogaia AB | 乳児疝痛を軽減するためのメラトニン支援細菌の選択及び使用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021531739A (ja) * | 2018-07-24 | 2021-11-25 | バイオガイア・エイビーBiogaia AB | 乳児疝痛を軽減するためのメラトニン支援細菌の選択及び使用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI20030467A0 (fi) * | 2003-03-28 | 2003-03-28 | Sirpa Jalkanen | Menetelmä tulehdustilojen hoitamiseen |
US7374924B2 (en) * | 2006-06-05 | 2008-05-20 | Biogaia Ab | Use of selected lactic acid bacteria for reducing infantile colic |
EP2609813A1 (en) * | 2011-12-30 | 2013-07-03 | Nestec S.A. | Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system |
ITMI20120471A1 (it) * | 2012-03-26 | 2013-09-27 | Giovanni Mogna | Composizione a base di ceppi di batteri bifidobacterium longum in grado di aiutare il prolungamento della vita |
GB201206599D0 (en) * | 2012-04-13 | 2012-05-30 | Univ Manchester | Probiotic bacteria |
EP2674162A1 (en) * | 2012-05-29 | 2013-12-18 | Danuta Kruszewska | Nanoproduct comprising lactobacillus reuteri dan080 useful in prophylaxis and medicine, both human and veterinary and medical use of the same |
WO2015112083A1 (en) * | 2014-01-23 | 2015-07-30 | Biogaia Ab | Selection of agents modulating gastrointestinal pain |
EP3145520A2 (en) * | 2014-05-20 | 2017-03-29 | Biogaia AB | Neonatal microbiome supplementation |
SG11201610413RA (en) * | 2014-06-30 | 2017-02-27 | Meiji Co Ltd | Lactic acid bacteria suppressing purine absorption and use thereof |
CA2971520C (en) * | 2014-12-23 | 2024-04-09 | Ilya Pharma Ab | Methods for wound healing |
CN110087656A (zh) * | 2016-05-27 | 2019-08-02 | 拜奥加亚公司 | 肌苷在治疗T-reg缺乏中的应用 |
WO2017223364A1 (en) * | 2016-06-23 | 2017-12-28 | Erdman Susan E | Canine microbe preparations for increasing oxytocin |
-
2019
- 2019-07-24 EP EP19742228.0A patent/EP3827102A1/en active Pending
- 2019-07-24 MX MX2020014222A patent/MX2020014222A/es unknown
- 2019-07-24 JP JP2021503787A patent/JP2021531015A/ja active Pending
- 2019-07-24 WO PCT/EP2019/069987 patent/WO2020020984A1/en unknown
- 2019-07-24 CA CA3103356A patent/CA3103356A1/en active Pending
- 2019-07-24 US US17/251,410 patent/US20230057324A1/en active Pending
- 2019-07-24 CN CN201980044643.7A patent/CN112739814B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021531739A (ja) * | 2018-07-24 | 2021-11-25 | バイオガイア・エイビーBiogaia AB | 乳児疝痛を軽減するためのメラトニン支援細菌の選択及び使用 |
Non-Patent Citations (1)
Title |
---|
JOURNAL OF EXPERIMENTAL MEDICINE, vol. 214, JPN6023021614, 2016, pages 107 - 123, ISSN: 0005077293 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021531739A (ja) * | 2018-07-24 | 2021-11-25 | バイオガイア・エイビーBiogaia AB | 乳児疝痛を軽減するためのメラトニン支援細菌の選択及び使用 |
JP7488199B2 (ja) | 2018-07-24 | 2024-05-21 | バイオガイア・エイビー | 乳児疝痛を軽減するためのメラトニン支援細菌の選択及び使用 |
Also Published As
Publication number | Publication date |
---|---|
US20230057324A1 (en) | 2023-02-23 |
CN112739814B (zh) | 2023-12-08 |
EP3827102A1 (en) | 2021-06-02 |
WO2020020984A1 (en) | 2020-01-30 |
MX2020014222A (es) | 2021-03-09 |
CA3103356A1 (en) | 2020-01-30 |
CN112739814A (zh) | 2021-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sun et al. | A potential species of next-generation probiotics? The dark and light sides of Bacteroides fragilis in health | |
Sun et al. | Lactic acid-producing probiotic Saccharomyces cerevisiae attenuates ulcerative colitis via suppressing macrophage pyroptosis and modulating gut microbiota | |
KR102371868B1 (ko) | 당뇨병 및 장 질환의 치료 또는 예방에 사용하기 위한 파에칼리박테리움 프라우스니치이 및 데설포비브리오 피거 | |
JP2021155458A (ja) | 細菌株を含む組成物 | |
JP2017535597A (ja) | 障害の微生物的処置および診断に関する方法および組成物 | |
Kim et al. | Lactobacillus plantarum CBT LP3 ameliorates colitis via modulating T cells in mice | |
AU2018397320B2 (en) | Serpin production | |
JP2021118687A (ja) | 新規のビフィドバクテリウムビフィダム菌株及び菌株由来多糖体 | |
Mohammad et al. | Atopic dermatitis: Pathophysiology, Microbiota, and Metabolome–a comprehensive review | |
US11602551B2 (en) | Use of inosine for the treatment of t-reg deficiency | |
CN112739814B (zh) | 使用能够增加腺苷水平的细菌菌株的治疗方法 | |
Li et al. | Microbiota-assisted therapy for systemic inflammatory arthritis: advances and mechanistic insights | |
TWI598103B (zh) | 改善困難梭狀桿菌感染症狀的發酵乳酸桿菌gmnl-296組合物及方法 | |
CN112236513B (zh) | 选择和使用褪黑素支持细菌以减少婴儿绞痛 | |
Han et al. | Minocycline induces tolerance to dendritic cell production probably by targeting the SOCS1/TLR4/NF-κB signaling pathway | |
WO2019129807A1 (en) | Serpin production | |
CN105358164B (zh) | 治疗和/或预防慢性炎症疾病的菌株 | |
Dhanoa | Probiotics for the management of rheumatoid arthritis | |
Kim et al. | Lactobacillus rhamnosus KBL2290 Ameliorates Gut Inflammation in a Mouse Model of Dextran Sulfate Sodium-Induced Colitis | |
Chaudhary et al. | Does “all disease begin in the gut”? The gut-organ cross talk in the microbiome | |
RU2815940C2 (ru) | Выбор и применение обеспечивающих мелатонин бактерий для снижения младенческих колик | |
US20240024376A1 (en) | Microorganisms synthesizing anti-inflammatory molecules | |
Wen et al. | Intestinal dysbacteriosis-propelled T helper 17 cells activation mediate the perioperative neurocognitive disorder induced by anesthesia/surgery in aged rats | |
Sun et al. | Lactic Acid-Producing Probiotic cerevisiae Saccharomyces Attenuates Ulcerative Colitis via Suppressing Macrophage Pyroptosis and Modulating Gut Microbiota | |
WO2023218355A1 (en) | Postbiotic-based composition for the treatment of tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220627 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220627 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230517 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230905 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230929 |